Form 4: Oncocyte CFO Andrea James Reports Stock Option and RSU Grant Following Stockholder Approval

Andrea James, CFO of Oncocyte Corp, reports the grant of stock options and restricted stock units (RSUs) following stockholder approval of an increase in shares available under the company's equity incentive plan.

Summary

• On October 15, 2024, Andrea James, the Chief Financial Officer of Oncocyte Corporation, filed a Form 4.
• The filing reports the grant of stock options and restricted stock units (RSUs) that were initially awarded on June 20, 2024, but were subject to stockholder approval.
• Stockholder approval for an increase in the number of shares available for issuance under the Oncocyte Corporation Amended and Restated 2018 Equity Incentive Plan was obtained on October 11, 2024.
• James was granted options to purchase 200,000 shares of common stock at an exercise price of $2.87.
• These options vest over time, with 25% vesting one year after the grant date (June 20, 2024) and the remaining 75% vesting in 36 equal monthly installments thereafter.
• James was also granted 100,000 restricted stock units (RSUs).

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of equity compensation is a standard practice and aligns management with shareholder interests. The vesting schedule promotes long-term commitment.

Positives

• The grant of stock options and RSUs aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options and RSUs.

Industry Context

Stock options and RSUs are common forms of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in publicly traded companies, particularly in the biotech sector.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) also utilize equity-based compensation to incentivize their executives.
• The vesting schedules and exercise prices are generally structured to align with industry norms and company-specific performance goals.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates